General description
Doxorubicin is an anthracycline antineoplastic agent, used in treatment protocols for various cancers.
INN
Doxorubicin
Medicine type
Chemical agent
EML status history
First added in 1977
(TRS
615)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Added in 2011
(TRS
965)
for
Lymphoid leukaemia, not elsewhere classified
Added in 2011
(TRS
965)
for
Burkitt lymphoma including Burkitt leukaemia
Added in 2015
(TRS
994)
for
Kaposi sarcoma of unspecified primary site
Added in 2015
(TRS
994)
for
Follicular lymphoma
Added in 2015
(TRS
994)
for
Malignant neoplasms of breast
Added in 2015
(TRS
994)
for
Diffuse large B-cell lymphomas
Added in 2015
(TRS
994)
for
Hodgkin lymphoma
Added in 2015
(TRS
994)
for
Malignant neoplasms of kidney, except renal pelvis
Added in 2015
(TRS
994)
for
Ewing sarcoma of bone and articular cartilage of unspecified sites
Added in 2015
(TRS
994)
for
Osteosarcoma of bone and articular cartilage of unspecified sites
Removed in 2015
(TRS
994)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Added in 2015
(TRS
994)
for
Other specified malignant neoplasms of breast
Added in 2019
(TRS
1021)
for
Plasma cell myeloma
Application rejected in 2021
(TRS
1035)
for
Rhabdomyosarcoma primary site
Wikipedia
DrugBank
Recommendations
Section
Cytotoxic medicines
- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Indications
Diffuse large B-cell lymphomas
Malignant neoplasms of breast
Hodgkin lymphoma
Kaposi sarcoma of unspecified primary site
Follicular lymphoma
Unspecified malignant neoplasms of ill-defined or unspecified sites
Osteosarcoma of bone and articular cartilage of unspecified sites
Ewing sarcoma of bone and articular cartilage of unspecified sites
Lymphoid leukaemia, not elsewhere classified
Malignant neoplasms of kidney, except renal pelvis
Burkitt lymphoma including Burkitt leukaemia
Other specified malignant neoplasms of breast
Plasma cell myeloma
Rhabdomyosarcoma primary site